Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia

Leukemia

Volumn 19, Issue 11, 2005, Pages 1887-1895

  Meier, M ^a   den Boer, M L ^a   Hall, A G ^b   Irving, J A E ^b   Passier, M ^a   Minto, L ^b   van Wering, E R ^c   Janka Schaub, G E ^d   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d Children's University Hospital ^*  (Germany)

Author keywords

ATM; DHPLC; Drug resistance; Outcome; T ALL

Indexed keywords

ATM PROTEIN; COMPLEMENTARY DNA; DAUNORUBICIN; MESSENGER RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG SENSITIVITY; EXON; GENE EXPRESSION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERM LINE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; T CELL LEUKEMIA; WILD TYPE;

EID: 27644562317     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403943     Document Type: Article

References (41)

1. Uziel T, Savitsky K, Platzer M, Ziv Y, Helbitz T, Nehls M et al. Genomic organization of the ATM gene. Genomics 1996; 33: 317-320.
2. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y et al. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997; 387: 516-519.
3. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281: 1674-1677.
4. Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 2000; 404: 613-617.
5. Gatei M, Scott SP, Filippovitch I, Soronika N, Lavin MF, Weber B et al. Role for ATM in DNA damage-induced phosphorylation of BRCA1. Cancer Res 2000; 60: 3299-3304.
6. Wang H, Guan J, Perrault AR, Wang Y, Iliakis G. Replication protein A2 phosphorylation after DNA damage by the coordinated action of ataxia telangiectasia-mutated and DNA-dependent protein kinase. Cancer Res 2001; 61: 8554-8563.
7. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, Hobson K et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 2003; 278: 14806-14811.
8. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97: 10389-10394.
9. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 14973-14977.
10. Bosotti R, Isacchi A, Sonnhammer EL. FAT: A novel domain in PIK-related kinases. Trends Biochem Sci 2000; 25: 225-227.
11. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, Hobson K et al. ATM associates with and phosphorylates p53: Mapping the region of interaction. Nat Genet 1998; 20: 398-400.
12. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523.
13. Lim DS, Kirsch DG, Canman CE, Ahn JH, Ziv Y, Newman LS et al. ATM binds to beta-adaptin in cytoplasmic vesicles. Proc Natl Acad Sci USA 1998; 95: 10146-10151.
14. Chen S, Paul P, Price BD. ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response. Oncogene 2003; 22: 6332-6339.
15. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 2001; 8: 1052-1065.
16. Meyn MS. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 1999; 55: 289-304.
17. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87: 423-438.
18. Pernin D, Bay JO, Uhrhammer N, Bignon YJ. ATM heterozygote cells exhibit intermediate levels of apoptosis in response to streptonigrin and etoposide. Eur J Cancer 1999; 35: 1130-1135.
19. Sugimoto K, Tamayose K, Takagi M, Yamada K, Sasaki M, Mizutani S et al. Activation of an ataxia telangiectasia mutation-dependent intra-S-phase checkpoint by anti-tumour drugs in HL-60 and human lymphoblastoid cells. Br J Haematol 2000; 110: 819-825.
20. Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
21. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, Kazemier KM et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 1994; 70: 1047-1052.
22. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.
23. Bernstein JL, Teraoka S, Haile RW, Borresen-Dale AL, Rosenstein BS, Gatti RA et al. Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat 2003; 21: 542-550.
24. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276.
25. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001; 3: 55-61.
26. Gumy-Pause F, Wacker P, Maillet P, Betts D, Sappino AP. ATM gene alterations in childhood acute lymphoblastic leukemias. Hum Mutat 2003; 21: 554.
27. Liberzon E, Avigad S, Stark B, Zilberstein J, Freedman L, Gorfine M et al. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosomes Cancer 2004; 39: 161-166.
28. Takeuchi S, Koike M, Park S, Seriu T, Bartram CR, Taub HE et al. The ATM gene and susceptibility to childhood T-cell acute lymphoblastic leukaemia. Br J Haematol 1998; 103: 536-538.
29. Luo L, Lu FM, Hart S, Foroni L, Rabbani H, Hammarstrom L et al. Ataxia-telangiectasia and T-cell leukemias: No evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. Cancer Res 1998; 58: 2293-2297.
30. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998; 58: 4552-4557.
31. Haidar MA, Kantarjian H, Manshouri T, Chang CY, O'Brien S, Freireich E et al. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 2000; 88: 1057-1062.
32. Vorechovsky I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997; 17: 96-99.
33. Stilgenbauer S, Schaffner C, Litterst A, Liebisch P, Gilad S, Bar-Shira A et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997; 3: 1155-1159.
34. Stoppa-Lyonnet D, Soulier J, Lauge A, Dastot H, Garand R, Sigaux F et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood 1998; 91: 3920-3926.
35. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748-753.
36. Stilgenbauer S, Winkler D, Ott G, Schaffner C, Leupolt E, Bentz M et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 1999; 94: 3262-3264.
37. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97: 2773-2778.
38. Stilgenbauer S, Schaffner C, Winkler D, Ott G, Leupolt E, Bentz M et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 2000; 11 (Suppl 1): 127-130.
39. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002; 99: 238-244.
40. Smith GC, d'Adda di Fagagna F, Lakin ND, Jackson SP. Cleavage and inactivation of ATM during apoptosis. Mol Cell Biol 1999; 19: 6076-6084.
41. Takagi M, Tsuchida R, Oguchi K, Shigeta T, Nakada S, Shimizu K et al. Identification and characterization of polymorphic variations of the ataxia telangiectasia-mutated (ATM) gene in childhood Hodgkin disease. Blood 2004; 103: 283-290.